In:
Hematological Oncology, Wiley, Vol. 40, No. 5 ( 2022-12), p. 1097-1099
Abstract:
This study reports the effectiveness of three injections of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine in 141 Allo‐HSCT recipients with a median follow‐up of 6 months post‐third shot. We demonstrate a long‐term high protection of Allo‐HSCT recipients since only 2 infections and one death related to COVID‐19 occurred.
Type of Medium:
Online Resource
ISSN:
0278-0232
,
1099-1069
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
2001443-0